Eli Lilly and Company announced today that the U.S. Food and Drug Administration (FDA) approved a single-injection, once-monthly maintenance regimen (200 mg/2 mL) of Omvoh (mirikizumab-mrkz) for ...
Omvoh now offers patients a simplified maintenance experience with one monthly injection, replacing the previous two-injection regimen Omvoh single-injection dosing ...
STIHL has issued a product recall on the BR 800 C-E Magnum petrol backpack blower as the fan wheel in affected units may fail ...
The new approvals bring the number of denosumab biosimilars in the US to eight, but price reductions are not yet substantial.
Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE: 532523, NSE: ...
The FDA has approved a new single-injection, once-monthly maintenance regimen for Eli Lilly’s Omvoh (mirikizumab-mrkz), ...
The Food and Drug Administration (FDA) has designated Stoboclo ® (denosumab-bmwo) and Osenvelt ® (denosumab-bmwo) as interchangeable biosimilars to the reference products Prolia ® (denosumab) and ...
The approval was based on a comprehensive clinical data package that included a phase 3 trial comparing denosumab-qbde with Prolia in 473 women with postmenopausal osteoporosis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback